{"id":"insulin-viaject-90","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"VIAject uses Biodel's proprietary VIA (Velocity and Insulin Administration) technology to enhance insulin absorption through the addition of excipients that modify subcutaneous tissue permeability. This allows insulin to enter the bloodstream more quickly, reducing the time to peak concentration and potentially improving postprandial glucose control in diabetic patients.","oneSentence":"Insulin VIAject is a rapid-acting insulin formulation designed to achieve faster absorption and onset of action compared to standard insulin injections.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:26.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01231984","phase":"NA","title":"Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles","status":"COMPLETED","sponsor":"Becton, Dickinson and Company","startDate":"2010-10","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":293},{"nctId":"NCT00849576","phase":"PHASE3","title":"Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Biodel","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insulin VIAject™ (90%)","genericName":"Insulin VIAject™ (90%)","companyName":"Biodel","companyId":"biodel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin VIAject is a rapid-acting insulin formulation designed to achieve faster absorption and onset of action compared to standard insulin injections. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}